Navigation Links
KTA Capital Advises SpringTree Global Investors on an AU$25.5 Million Investment in Prima BioMed Ltd
Date:7/22/2009

SpringTree Special Opportunities Fund, LP ("SpringTree") announced today its AU$25,500,000 investment in Prima BioMed Ltd (ASX:PRR), an Australian Securities Exchange-listed oncology biotechnology company. KTA Capital acted as the exclusive financial advisor to SpringTree's general partner SpringTree Global Investors, LLC on the transaction. A copy of Prima BioMed Ltd's public announcement follows.

New York (PRWEB) July 22, 2009 -- SpringTree Special Opportunities Fund, LP ("SpringTree") announced today its AU$25,500,000 investment in Prima BioMed Ltd (ASX:PRR), an Australian Securities Exchange-listed oncology biotechnology company. KTA Capital acted as the exclusive financial advisor to SpringTree's general partner SpringTree Global Investors, LLC on the transaction. To view a copy of Prima BioMed Ltd's public announcement please click here http://www.asx.com.au/asxpdf/20090721/pdf/31jn69xw14p8wy.pdf.

About KTA Capital, LLC
KTA Capital is an investment bank headquartered in New York, USA. Its services include international investment banking across a wide range of industries, both in the equity capital and debt markets, as well as M&A advisory. In its business it leverages its relationships with literally hundreds of institutional investors, including hedge funds, mutual funds, private equity funds, venture capital funds, bond funds, mezzanine debt funds, private placement funds, investment advisers, national, regional and international banks, acquisitive industry participants and strategic cornerstone investors, family offices, merchant banks and sovereign wealth funds. KTA Capital is registered as a broker-dealer with the United States Securities and Exchange Commission and is a member of Financial Industry Regulatory Authority, Inc. (" FINRA").

Media Contact:
Eugene Tablis
Tel.: +1 646 707 4177

About SpringTree Global Investors, LLC
SpringTree Global Investors, LLC ( www.springtreegi.com ) is a New York-based asset management company that makes debt and equity investments in public companies around the world with a focus on small-cap and mid-cap companies requiring US$5-US$150 million in debt and/or equity. It invests across a broad range of industries and a wide range of geographies and economic environments.

Contact:
Jeffrey Easton
Tel.: +1 212 255 3552

###

Read the full story at http://www.prweb.com/releases/2009/07/prweb2664694.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Viral Genetics Retires Nearly $3.5 Million Convertible Debt and Provides Updates on Capital Structure and Stock Issuances
2. AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS
3. Top CEOs Declare Americas Manufacturing Sector Requires Pro-Industry Policies, Capital Management and Innovation to Maintain Economic Leadership
4. Venture Capitalists to Invest in Promising PA Life Science Companies, Governor Rendell Says
5. Venture Capital Veteran John Brooks Joins Life Science Investment Bank Johnston Blakely & Company
6. Cell Therapeutics Satisfies NASDAQ Listing Requirements to Continue to Trade on NASDAQ Capital Market
7. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
8. Merck Serono Launches Strategic Venture Capital Fund
9. BioRelix and Dalton Medicinal Chemistry Expand and Renew Research Agreement to Capitalize on Riboswitches
10. Kendle to Present at Upcoming Barclays Capital and Raymond James Conferences
11. Schering-Plough to Webcast Presentation at Barclays Capital Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
KTA Capital Advises SpringTree Global Investors on an AU$25.5 Million Investment in Prima BioMed Ltd
(Date:2/12/2016)... , Feb. 12, 2016  PTC Therapeutics, Inc. ... annual STRIVE (Strategies to Realize Innovation, Vision and ... (DMD). STRIVE provides funds to patient advocacy organizations ... make meaningful contributions to the rare disease community ... of future patient advocates. Mary ...
(Date:2/11/2016)... and GERMANTOWN, Maryland , ... Frankfurt Prime Standard: QIA) today announced the introduction of ... gene expression profiling, expanding QIAGEN,s portfolio of Sample to ... researchers to select from over 20,000 human genes and ... between genes, cellular phenotypes and disease processes. --> ...
(Date:2/11/2016)... 2016  Dovetail Genomics™ LLC today announced that it ... a planned metagenomic genome assembly service. Richard Green ... assembly method in a talk on Friday, February 12 ... conference in Orlando, Fla. ... is difficult. Using its proprietary Chicago ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... of its new stem cell treatment clinic in Quito, Ecuador. The new facility ... and trauma applications to patients from around the world. , The new ...
Breaking Biology Technology:
(Date:2/2/2016)... Checkpoint Inhibitors for Cancer – Explore ... you interested in the future of cancer drugs? ... Visiongain,s report gives those predictions to 2026 at ... Avoid falling behind in data or losing ... those emerging cancer therapies can achieve. There you ...
(Date:2/1/2016)... 1, 2016  Today, the first day of American ... to develop a first of its kind workplace health ... Watson. In the first application of Watson ... IBM ), and Welltok will create a new offering ... cognitive analytics, delivered on Welltok,s health optimization platform. The ...
(Date:1/25/2016)... 2016  Glencoe Software, the world-leading supplier of image ... will provide the data management solution OMERO Plus for ... Photo - ... Phenotypic analysis measures the characteristics and behavior ... between states such as health and disease, the presence ...
Breaking Biology News(10 mins):